MIA takes centre stage at leading cancer conference
5 June 2019
Researchers from Melanoma Institute Australia (MIA) took centre stage at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, attended by over 40,000 professionals. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
Four independent presentations on melanoma
“Four presentations from one institution, including a Clinical Science Symposium,
Dr Da Silva’s research is paving the way for personalised therapies, as she unveiled a detailed analysis of melanoma biomarkers to predict treatment response.
“These outliers are so important to our research. These are the patients who can teach us about resistance or conversion to therapy, which is our next big research focus,” said Professor Richard Scolyer, Co-Medical Director of MIA.
Another MIA presentation outlined what researchers hope will be the new benchmark for drug testing and regulatory approval. MIA’s Associate Professor Alex Menzies presented analyses of data from six
MIA medical oncology fellow Dr Carina Owen presented the analysis from her study looking at international data of patients who recur on adjuvant immunotherapy (immunotherapy given after surgical intervention). Her analysis reveals that patients who recur after stopping treatment early or completing their therapy may respond to further immunotherapy.
Professor Angela Hong also presented the results from MIA’s whole brain radiotherapy (WBRT) trial. The international Phase III trial found that WBRT does not prolong overall survival compared to observation. As WBRT can be morbid, using this information as the foundation for treatment changes will improve the quality of life for patients whose melanoma has spread to the brain.
In the melanoma and skin cancer poster session, MIA was again well-represented with six posters on display. Professor Long presented two posters summarising new and further results from clinical trials. The newest cohort of patients on the Keynote-029 study have
A poster by Dr
Associate Professor Matt Carlino presented the outline of a new clinical trial, where giving patients with resected Stage II melanoma adjuvant
“We’re exceptionally proud of our ASCO presenters. Each one is pushing forward the treatment landscape for our patients and edging closer to our goal of zero deaths from melanoma,” said Professor Long.
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Honouring Ben's life by supporting the next generation of melanoma researchers
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
MIA's annual Research Retreat 2021
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Understanding the needs of Stage III melanoma patients when choosing treatments.
Independent researchers at The University of Sydney are seeking patient feedback.
Community Fundraising Wrap Up Apr-June 2021
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Patients paying it forward
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
Research boost to improve outcomes for melanoma patients
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Amie St Clair 10th Annual Ball
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina Melanoma Ride
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Melanoma Clinical Trial to open in Wagga
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
Queen's Birthday Honour for Professor Richard Scolyer
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
Sharing our research on the global stage at 2021 ASCO Annual Meeting
Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21.
Australian researchers lead world in successful trial of new cancer treatment.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Thank you doesn't seem enough for our melanoma nurses.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA shared their knowledge at the virtual 10th World Congress of Melanoma.
Community Fundraising Wrap Up Jan-Mar 2021
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.